Presentation is loading. Please wait.

Presentation is loading. Please wait.

Chronic PDGFRα activation reduces sensitivity of PDGFRα-positive GBM cells to translational inhibitor–induced suppression on cell viability. Chronic PDGFRα.

Published byEdwin Burke Modified over 5 years ago

Similar presentations

Presentation on theme: "Chronic PDGFRα activation reduces sensitivity of PDGFRα-positive GBM cells to translational inhibitor–induced suppression on cell viability. Chronic PDGFRα."— Presentation transcript:

1 Chronic PDGFRα activation reduces sensitivity of PDGFRα-positive GBM cells to translational inhibitor–induced suppression on cell viability. Chronic PDGFRα activation reduces sensitivity of PDGFRα-positive GBM cells to translational inhibitor–induced suppression on cell viability. (A–C) Cell viability of PDGFRα GBM primary cell culture with the treatment of 4EGI-1, AZD8055, and LY , respectively, under control or chronic PDGFRα stimulation. (D–F) Cell viability of EGFR GBM primary cell culture with the treatment of 4EGI-1, AZD8055, and LY , respectively, under control or chronic PDGFRα stimulation. Cells were treated with the indicated translational inhibitors for 48 h in serum-deficient media, and the cell viability was assessed using the CellTiter-Fluor Cell Viability Assay. Data represent the mean ± SD of triplicate experiments. The statistical differences were determined using paired t test. *P < 0.05. Shuang Zhou et al. LSA 2018;1:e © 2018 zhou et al.

Download ppt "Chronic PDGFRα activation reduces sensitivity of PDGFRα-positive GBM cells to translational inhibitor–induced suppression on cell viability. Chronic PDGFRα."

Similar presentations

ABAE positive cells 6h after treatment

ABAE positive cells 6h after treatment
A PC-9 PC-9/AR B PC-9/GR PC-9/GR/AR AZD9291 AZD9291 AZD9291 AZD9291

A PC-9 PC-9/AR B PC-9/GR PC-9/GR/AR AZD9291 AZD9291 AZD9291 AZD9291
RGFP-966 decreases HDAC3 activity and is not cytotoxic.

RGFP-966 decreases HDAC3 activity and is not cytotoxic.
Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC  Manish R.

Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC  Manish R.
DHEA(S) and Allo protected rat chromaffin cells in culture against serum deprivation-induced apoptosis. DHEA(S) and Allo protected rat chromaffin cells.

DHEA(S) and Allo protected rat chromaffin cells in culture against serum deprivation-induced apoptosis. DHEA(S) and Allo protected rat chromaffin cells.
Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific.

Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific.
Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.
PDGFRα GBM primary cultures demonstrate titratable and temporal DOX-inducible expression of hPDGF-A and receptor activation. PDGFRα GBM primary cultures.

PDGFRα GBM primary cultures demonstrate titratable and temporal DOX-inducible expression of hPDGF-A and receptor activation. PDGFRα GBM primary cultures.
PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.
Effects of neuropeptide treatment on APC stimulation of Ag-specific T cells. Effects of neuropeptide treatment on APC stimulation of Ag-specific T cells.

Effects of neuropeptide treatment on APC stimulation of Ag-specific T cells. Effects of neuropeptide treatment on APC stimulation of Ag-specific T cells.
Role of IL-27 in expression of PD-L1, LAG-3, and CTLA-4 depends on strength of α-CD3/28 signaling. Role of IL-27 in expression of PD-L1, LAG-3, and CTLA-4.

Role of IL-27 in expression of PD-L1, LAG-3, and CTLA-4 depends on strength of α-CD3/28 signaling. Role of IL-27 in expression of PD-L1, LAG-3, and CTLA-4.
Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.
BIRC6 confers resistance against cisplatin and oxaliplatin.

BIRC6 confers resistance against cisplatin and oxaliplatin.
STING stimulation in T cells inhibits cell cycle progression.

STING stimulation in T cells inhibits cell cycle progression.
mTORC1 signaling is required for STING-mediated type I IFN responses.

mTORC1 signaling is required for STING-mediated type I IFN responses.
Array-Based Functional Screening of Heparin Glycans

Array-Based Functional Screening of Heparin Glycans
Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 3. TKI sensitivity assessed by the MANO method.
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
Growth of TKI‐resistant EGFR delE746‐A750 PC‐9 NSCLC cells is associated with elevated cellular free fatty acid and expression of FASN, and is suppressed.

Growth of TKI‐resistant EGFR delE746‐A750 PC‐9 NSCLC cells is associated with elevated cellular free fatty acid and expression of FASN, and is suppressed.
Prazosin inhibits GIC survival

Prazosin inhibits GIC survival

Similar presentations

Ads by Google